Terns Pharma (NASDAQ: TERN)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-15 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.640 | -0.550 | 0.0900 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Terns Pharma (NASDAQ: TERN) through any online brokerage.
Other companies in Terns Pharma’s space includes: Cumberland (NASDAQ:CPIX), Iterum Therapeutics (NASDAQ:ITRM), Cocrystal Pharma (NASDAQ:COCP), Akanda (NASDAQ:AKAN) and Jaguar Health (NASDAQ:JAGX).
The latest price target for Terns Pharma (NASDAQ: TERN) was reported by JP Morgan on Wednesday, March 23, 2022. The analyst firm set a price target for 6.00 expecting TERN to rise to within 12 months (a possible 282.17% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Terns Pharma (NASDAQ: TERN) is $1.57 last updated May 23, 2022, 8:00 PM UTC.
There are no upcoming dividends for Terns Pharma.
Terns Pharma’s Q2 earnings are confirmed for Monday, August 15, 2022.
There is no upcoming split for Terns Pharma.
Terns Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.